By Fineline Cube Luye Pharma Group Limited (HKG: 2186) announced that its Category 1 candidate drug LY03015 has met the primary endpoint in a China Phase II clinical trial for the treatment of tardive dyskinesia (TD). The world’s first innovative drug targeting both vesicular monoamine transporter 2 (VMAT2) and Sigma-1R demonstrated a breakthrough 76.5% response rate in the highest dose group, significantly outperforming historical treatment outcomes for this debilitating movement disorder.
Clinical Trial Milestone
| Item | Detail |
|---|---|
| Company | Luye Pharma Group Limited (HKG: 2186) |
| Drug Candidate | LY03015 – Category 1 innovative drug |
| Trial Phase | Phase II, multicenter, randomized, double-blind, placebo-controlled |
| Primary Indication | Tardive dyskinesia (TD) |
| Patient Population | 121 patients with moderate-to-severe TD |
| Treatment Duration | 6 weeks |
| Primary Endpoint | Response rate measured by Abnormal Involuntary Movement Scale (AIMS) |
| Highest Response Rate | 76.5% (20 mg dose group) |
Product Profile & Mechanism of Action
Dual-Target Innovation
- First-in-Class: World’s first drug entering clinical development targeting both VMAT2 and Sigma-1R simultaneously
- Mechanism: Potently reduces dopamine release from presynaptic neurons while promoting synaptic remodeling and repairing synaptic connections
- Dual Effects: Combines immediate symptom control with potential pathological improvement
- Additional Indications: Also being developed for chorea associated with Huntington’s disease (HD)
Clinical Differentiation
- Target Population: Addresses TD caused by long-term antipsychotic medication use
- Disease Burden: Hyperkinetic movement disorder significantly impacting quality of life
- Current Treatment Gap: Limited effective options with suboptimal response rates in existing therapies
Phase II Results & Dose-Response Analysis
Efficacy Outcomes by Dose Group
- 5 mg group: 25.9% response rate
- 10 mg group: Statistically significant improvement vs. placebo (P < 0.01)
- 20 mg group: 76.5% response rate with statistically significant difference vs. placebo (P < 0.01)
- Dose-Response Relationship: Clear correlation between dose escalation and improved response rates
Safety & Tolerability Profile
- Rebound Effect: Relatively small rebound effect observed after drug discontinuation
- Overall Safety: Good safety and tolerability maintained throughout the 6-week treatment period
- Adverse Events: No serious safety concerns reported in any dose group
Market Impact & Competitive Landscape
- TD Market Opportunity: Affects approximately 500,000+ patients in China alone, with limited treatment options
- Breakthrough Potential: 76.5% response rate represents substantial improvement over current standard-of-care therapies
- First-Mover Advantage: Dual-target mechanism provides significant competitive differentiation in neuropsychiatric disorders
- Regulatory Pathway: Category 1 designation in China supports expedited development and potential premium pricing
- Global Expansion Potential: Successful China data may support international regulatory filings for both TD and Huntington’s disease indications
Strategic Outlook
The exceptional Phase II results position LY03015 as a potential game-changer in the treatment of tardive dyskinesia, addressing a significant unmet medical need with unprecedented efficacy. Luye Pharma’s dual-target approach represents a paradigm shift from symptomatic management to potential disease modification in movement disorders. The clear dose-response relationship and favorable safety profile support advancement to Phase III development, while the Category 1 innovative drug status in China provides substantial regulatory and commercial advantages. This breakthrough also validates Luye’s innovative R&D capabilities in complex neurological disorders beyond its traditional psychiatric franchise.
Forward‑Looking Statements
This brief contains forward-looking statements regarding clinical development, regulatory pathways, and commercial potential. Actual results may differ due to Phase III trial outcomes, regulatory decisions, competitive dynamics, and market acceptance.-Fineline Info & Tech